Oclassen Pharmaceuticals
Executive Summary
Granted exclusive worldwide license from Memorial Sloan-Kettering to develop and market two fluorinated pyramidine antiviral agents -- FIAC (fluoro-iodo-arabinosylcytosine) and FIAU (fluori-iodo-arabinosyluriacil). FIAC, which can be administered both orally and intravenously, will initially be developed for cytomegalovirus infections in AIDS patients. FIAU has already been studied in about 100 patients under a development agreement with Bristol-Myers that was discontinued in 1985. Oclassen's clinical studies are scheduled to begin within six months.